Evidence map›Paper›PMID 35123659›Full record

ArticleThe Lancet. Respiratory medicine2022

Baricitinib for patients with severe COVID-19-time to change the standard of care?

Alexander Supady, Robert Zeiser

Abstract readComment
In one paragraph

Article in The Lancet. Respiratory medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Alexander SupadyDepartment of Medicine III, Interdisciplinary Medical Intensive Care, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau 79106, Germany; Department of Cardiology and Angiology I, Heart Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau 79106, Germany; Heidelberg Institute of Global Health, University of Heidelberg, Heidelberg, Germany. Electronic address: alexander.supady@uniklinik-freiburg.de.
Robert ZeiserDepartment of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau 79106, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AzetidinesCOVID-19 Drug TreatmentHumansPurinesPyrazolesStandard of CareSulfonamidesAzetidinesbaricitinibPurinesPyrazolesSulfonamides

Identifiers

PMID35123659
PMCPMC8813061

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.